Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials

被引:117
作者
Correll, Christoph U. [1 ]
机构
[1] Zucker Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Glen Oaks, NY 11004 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
bipolar disorder; second-gene ration antipsychotics; mood stabilizers; weight gain; metabolic abnormalities;
D O I
10.1097/chi.0b013e318040b25f
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Objective: To review weight and metabolic effects of mood-stabilizing treatments in pediatric bipolar disorder. Method: Systematic PubMed/fidedfine search of studies reporting on change in weight and/or glucose/lipid values with mood-stabilizing drugs in at least nine pediatric patients with bipolar disorder. Results: Nineteen studies, including 24 medication trials in 684 patients (mean age, 12.3 +/- 2.9 years) were included. Youngsters received lithium, antiepileptics, or their combinations (n = 459), or second-generation antipsychotics, alone or combined with lithium or divalproex (n = 225), for 4 to 48 (mean, 15.4 +/- 12.7) weeks. Weight increase was significant/clinically relevant in 18 (75.0%) trials. Weight loss was significant with topiramate (2 studies, 38 subjects) and present with aripiprazole (1 study, 14 subjects). In trials lasting <= 12 weeks, weight gain was greater with second-generation antipsychotics plus mood stabilizers (5.5 +/- 1.8 kg) compared to mood-stabilizer monotherapy (1.2 +/- 1.9 kg, p < .05, Cohen's d = 2.33) or mood-stabilizer cotreatment (2.1 +/- 1.3 kg, p < .05, Cohen's d = 2.17), but not compared to antipsychotic monotherapy (3.4 +/- 1.3 kg, p > .05, Cohen's d = 1.34). Nonfasting glucose/lipid changes were nonsignificant in two second-generation antipsychotic trials (n = 61, 8.9%). Conclusions: Data are sparse regarding body composition effects and lacking for fasting metabolic effects of mood stabilizers in pediatric bipolar disorder. Combining antipsychotics with mood stabilizers seems to lead to greater weight gain than treatment with one or two mood stabilizers.
引用
收藏
页码:687 / 700
页数:14
相关论文
共 64 条
[1]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[2]  
[Anonymous], 2004, J CLIN PSYCHIAT, V65, P267
[3]  
BAO WH, 1994, ARCH INTERN MED, V154, P1842
[4]   The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: A retrospective chart review [J].
Barzman, DH ;
DelBello, MP ;
Kowatch, RA ;
Gernert, B ;
Fleck, DE ;
Pathak, S ;
Rappaport, K ;
Delgado, SV ;
Campbell, P ;
Strakowski, SM .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2004, 14 (04) :593-600
[5]   Medication use in children and adolescents treated in the community for bipolar disorder [J].
Bhangoo, RK ;
Lowe, CH ;
Myers, FS ;
Treland, J ;
Curran, J ;
Towbin, KE ;
Leibenluft, E .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (04) :515-522
[6]   Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children [J].
Biederman, J ;
Mick, E ;
Hammerness, P ;
Harpold, T ;
Aleardi, M ;
Dougherty, M ;
Wozniak, J .
BIOLOGICAL PSYCHIATRY, 2005, 58 (07) :589-594
[7]   An open-label trial of risperidone in children and adolescents with bipolar disorder [J].
Biederman, J ;
Mick, E ;
Wozniak, J ;
Aleardi, M ;
Spencer, T ;
Faraone, SV .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (02) :311-317
[8]  
Bowden CL, 2005, J CLIN PSYCHIAT, V66, P12
[9]   An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression [J].
Chang, K ;
Saxena, K ;
Howe, M .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (03) :298-304
[10]   A POWER PRIMER [J].
COHEN, J .
PSYCHOLOGICAL BULLETIN, 1992, 112 (01) :155-159